Vimarsana
Biggest News Aggregation in the World

Page 35 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

DGAP-News: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Issuer: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis

Mid-Morning Market Update: Markets Open Lower; Hormel Foods Earnings Top Views - Vimarsana News

Mid-Morning Market Update: Markets Open Lower; Hormel Foods Earnings Top Views

U.S. stocks traded lower this morning, with the Dow Jones dropping 200 points on Thursday. Following the market opening Thursday, the Dow traded ...

Immunic : Phase 2 Trial Of Vidofludimus Calcium On Ulcerative Colitis Fails To Meet Primary Goal - Vimarsana News

Immunic : Phase 2 Trial Of Vidofludimus Calcium On Ulcerative Colitis Fails To Meet Primary Goal

(RTTNews) - Immunic Inc. (IMUX) said Thursday that phase 2 CALDOSE-1 trial of vidofludimus calcium did not achieve primary endpoint in patients wi...

Related Topics:
Immunic Inc
Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and...

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share - Vimarsana News

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share

Wall Street brokerages expect Immunic, Inc. (NASDAQ:IMUX – Get Rating) to post earnings per share of ($0.76) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Immunic’s earnings, with estimates ranging from ($0.93) to ($0.58). Immunic posted earnings per share of ($0.82) in the same quarter last year, which […]